Notícias e Atividades da Castle Biosciences
Presença
Castle Biosciences é uma das ...
Castle Biosciences é uma empresa listada sob o símbolo CSTL (US).
Executivos
Veja o organograma con seus 28 executivos principais
Biografias mais buscadas da Castle Biosciences
- Derek Maetzold, Director, President and Chief Executive Officer
- Miles Harrison, Director
- Tiffany Olson, Director
Criar um alerta
para seguir os movimentos de executivos da Castle Biosciences.
Biotecnologia
Castle Biosciences possui 2.351 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Genus (Reino Unido).
Popular M&A news in Biotecnologia
- Transcarent and Accolade have merged (publicado em 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
- Atsena Therapeutics acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 4 de abril de 2025).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Castle Biosciences
- Castle Biosciences Honored with a Top Workplaces USA Award for Fourth Consecutive Year
- Castle Biosciences Strengthens Commitment to Esophageal Cancer Awareness Through Collaborative Partnerships
- Publication of Data from Prospective, Multicenter Study Demonstrates Positive Survival Outcomes in Patients with Low-Risk Melanoma Who Avoided Sentinel Lymph Node Biopsy with Information from Castle Biosciences’ DecisionDx®-Melanoma Test
- Castle Biosciences to Present New Data at EADO Supporting the Clinical Value of the DecisionDx®-Melanoma Test in Guiding Risk-Aligned Management of Patients with Melanoma
- Castle Biosciences' DecisionDx®-SCC Data Earns Top Five Abstract at NCCN 2025, Shows Significantly Enhanced Risk Stratification Beyond Current Staging Within NCCN Risk Groups
- New Data to be Presented at the 2025 American Academy of Dermatology (AAD) Annual Meeting Further Strengthens Evidence Supporting the Clinical Value of Castle Biosciences' Dermatology Portfolio
- Castle Biosciences Reports Fourth Quarter and Full-Year 2024 Results
- Castle Biosciences to Participate in Upcoming Investor Conferences
- Castle Biosciences to Share Data Reinforcing the Clinical Value of Its Dermatologic Portfolio of Gene Expression Profile Tests at the 22nd Annual Winter Clinical Dermatology Conference - Hawaii®
- Castle Biosciences to Release Fourth Quarter and Full-Year 2024 Financial Results and Host Conference Call on Thursday, Feb. 27, 2025
- View more press releases Close
Redes sociais sobre Castle Biosciences
- Castle Biosciences na Wikipedia, Google News e Yahoo Finance
- Castle Biosciences na LinkedIn, Twitter e YouTube
